Moreover, results from a randomized trial enrolling 211 breast cancer patients undergoing neoadjuvant epirubicin therapy showed upregulated expression of PHD1, PHD2 and PHD3, together with HIF-1α, VEGF and carbonic anhydrase IX (CAIX) [120]. The gene discussed is CA9; the disease is breast cancer.